Do not use for HLA-related disease screening or diagnosis (eg, celiac disease, narcolepsy, rheumatologic diseases). To rule out celiac disease (when other testing is inconclusive), refer to Celiac Disease (HLA-DQ2 and HLA-DQ8) Genotyping (2005018). When narcolepsy is suspected in symptomatic individuals, refer to Narcolepsy (HLA-DQB1*06:02) Genotyping (2005023).
- Patient Preparation
- Lavender (EDTA), pink (K2EDTA), or yellow (ACD Solution A or B).
- Specimen Preparation
- Transport 5 mL whole blood. (Min: 3 mL)
- Storage/Transport Temperature
- Unacceptable Conditions
- Specimens collected in green (sodium or lithium heparin).
- Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
Purpose: For immunization/vaccination trials or to aid the clinical diagnosis of diseases strongly associated with the HLA-DQB locus.
Methodology: PCR followed by Sequence Specific Oligonucleotide Probe Hybridization of HLA-DQB locus.
Analytical Sensitivity & Specificity: Medium to high resolution of HLA-DQB locus.
Limitations: The presence of a disease-associated HLA combination does not establish a diagnosis. If less than 2 alleles are reported for a locus, the patient is likely homozygous. Rare diagnostic errors can occur due to primer or probe site mutations. This test is not sufficient for comprehensive HLA evaluation for clinical hematopoietic stem cell transplantation (refer to HLA Class I (ABC) by Next Generation Sequencing-2011264 and/or HLA Class II (DRB1 and DQB1) by Next Generation Sequencing-2011272 ).
Counseling and informed consent are recommended for genetic testing. Consent forms are available online at www.aruplab.com.
|Component Test Code*||Component Chart Name||LOINC|
|2002811||HLA Class II, Locus DQB*, Allele 1||43291-4|
|2002812||HLA Class II, Locus DQB*, Allele 2||43291-4|
|2002813||HLA-DQB Genotyping Interpretation||53938-7|
Performed at UUHC - H&I Lab